In another setback in the lucrative lung cancer market, Bristol-Myers Squibb (BMY) said Thursday that it is withdrawing its application with the Food and Drug Administration to use its cancer immunotherapy blockbuster, Opdivo, in combination with Yervoy, a second Bristol drug, for some patients with previously untreated non-small cell lung cancer.

The news comes as Bristol is announcing strong fourth-quarter earnings, with sales up 10 percent from last year to $6 billion and earnings per share excluding items of 94 cents, 10 cents ahead of the expectations of analysts polled by FirstCall. Sales of Opdivo increased 33 percent to $1.8 billion in the quarter, helping to drive the strong quarter. The company’s announcement also comes just weeks after it said it would purchase rival cancer drug maker Celgene for $74 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy